Oxaliplatin News and Research

RSS
Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Strategies to minimize side effects of oxaliplatin in metastatic colon cancer

Strategies to minimize side effects of oxaliplatin in metastatic colon cancer

Adding oxaliplatin to adjuvant 5FU improves survival of patients with stage III colon cancer

Adding oxaliplatin to adjuvant 5FU improves survival of patients with stage III colon cancer

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen receives EC approval to extend therapeutic indications for Vectibix

Conference highlights advances in evidence-based integrative therapies for cancer

Conference highlights advances in evidence-based integrative therapies for cancer

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

UNC's new nanoparticle shows potential for cancer chemotherapy

UNC's new nanoparticle shows potential for cancer chemotherapy

Combination of lunasin and oxaliplatin prevents colon cancer from metastasis

Combination of lunasin and oxaliplatin prevents colon cancer from metastasis

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck submits Erbitux indication extension to EMA for NSCLC treatment